A female infant presented with polydipsia, glucosuria, ketoacidosis (pH 7.09, −14 mmol/l base excess) and severe hyperglycemia (blood glucose 42.5 mmol/l [766 mg/dl]) 12 weeks after birth. C peptide was undetectable. Tests for islet cell autoantibodies and antibodies against glutamic acid decarboxylase 65 (GAD65), insulinomaassociated antigen 2 and insulin were negative. The patient had no family history of diabetes. She had a low birth weight (2,700 g) despite an unremarkable pregnancy and a normal gestational age. For the first 72 h after diagnosis of neonatal diabetes she was treated with intravenous insulin (2.1 U/kg, 1.5 U/kg and 1.2 U/kg body weight, for the first, second and third days, respectively). Subsequently, she received subcutaneous insulin therapy with multiple insulin injections daily (1.3 U/kg body weight daily). She had frequent episodes of hyperglycemia and hypoglycemia (blood glucose 1.1-24.8 mmol/l [19. .8 mg/dl]) from the time of diabetes onset to the age of around 3 years, and experienced two severe hypoglycemic episodes (blood glucose 1.1 mmol/l [19.8 mg/dl] on each occasion), one at 2 years of age and one at 4 years of age. The first episode was associated with loss of consciousness following physical activity and the second with night-time hypoglycemia. On both occasions the patient was treated with glucagon (0.5 mg) and no hospitalization was needed. No further episodes of ketoacidosis were documented. The patient's level of hemoglobin A1c (Hb A1c ) averaged 6.9% between 6 months and 6 years of diabetes duration (see Supplementary  Table 1 
online).
The patient's motor and mental functions were normal at diabetes diagnosis, but at 12 months of age she was still unable to stand without support and her motor milestones were similar Background A 12-week-old female presented with neonatal diabetes. Insulin therapy alleviated the diabetes, but the patient showed marked motor and mental developmental delay. The patient underwent genetic evaluation at the age of 6 years, prompted by reports that mutations in the KCNJ11 gene caused neonatal diabetes.
Investigations Genomic sequencing of the ATP-sensitive potassium (K ATP ) channel gene KCNJ11 and in vitro functional analysis of the channel defect, and single-photon emission CT imaging before and after glibenclamide therapy.
Diagnosis Genetic evaluation revealed a missense mutation (His46Leu) in KCNJ11, which encodes the Kir6.2 subunit of the K ATP channel, conferring reduced ATP sensitivity. Functional studies demonstrated that the mutant channels were strongly inhibited by the sulfonylurea tolbutamide.
Management Sulfonylurea (glibenclamide) treatment led to both improved glucose homeostasis and an increase in mental and motor function.
to those of a normally developing child aged 8-10 months. No specific neurological features were found and the native electroencephalogram was normal. Importantly, developmental delay was evident before the first hypoglycemic episode. At the age of 24 months, a pediatric neurological examination revealed muscle weakness and lower limb hypotonia. The patient's reflexes and sensation were normal.
The patient underwent genetic evaluation at the age of 6 years, following reports that mutations in the KCNJ11 gene (which encodes the ATP-sensitive potassium channel Kir6.2 subunit) caused neonatal diabetes. 1, 2 At this time, the patient reportedly fell down 10-15 times per week and had difficulty running. The falls were not associated with loss of consciousness or seizures, and an electroencephalogram was normal. Muscle weakness and hypotonia of the lower extremities were still present: muscle power was graded as 3-4 on a scale of 0-5 for muscle power assessment in a cooperative child. At this time the patient also had difficulty sustaining attention. Psychological examination revealed that she fulfilled seven criteria for inattention and eight criteria for hyperactivity-impulsivity according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition) diagnostic criteria for attention deficit hyperactivity disorder (ADHD). She showed mental retardation (using the Wechsler Preschool and Primary Scale of Intelligencerevised [WPPSI-R] test), demonstrating an IQ of 57 and mental abilities similar to those of a normal child aged 42-48 months.
An MRI scan revealed no brain structural abnormalities (see Supplementary Figure 1 online). Single-photon emission computed tomography (SPECT) examination, however, showed a focal perfusion deficit in the left temporal cortex ( Figure 1A ). Cerebellar indices were calculated for semi-quantitative evaluation of SPECT scans ( Figure 1C,D) .
Sequencing of the patient's KCNJ11 gene using genomic DNA extracted from peripheral lymphocytes identified a novel heterozygous mutation, His46Leu (c137A>T) in Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (K ATP ) channel (Figure 2A,B) . 2 Genotype analysis confirmed the family relationships, and that the His46Leu mutation was not present in either parent. In vitro functional studies determined that the His46Leu mutation reduced K ATP channel sensitivity to ATP, and that the mutant channels were strongly inhibited by the sulfonylurea tolbutamide ( Figure 2E and Supplementary Information 1 online). On the basis of the genotype and the clinical features of neonatal diabetes plus developmental delay, the patient was given a diagnosis of intermediate DEND (developmental delay, epilepsy and neonatal diabetes) syndrome.
Glibenclamide treatment was initiated because of the observed sensitivity of the mutant K ATP channel to sulfonylureas in studies carried out in vitro. The initial dose was 0.1 mg/kg body weight daily, divided into three doses (see Supplementary Information 1 online), and this was gradually increased. The insulin dose was reduced concomitantly. During the transition period, a transitory diarrhea (lasting less than 3 days) without pyrexia was noted (as reported previously in other patients). 3 Insulin was discontinued 1 month after initiating the transition to glibenclamide and good diabetes control (Hb A1c level of 5.9% 4 months after initiation of glibenclamide therapy) was obtained with a sulfonylurea dose of 0.81 mg/kg body weight daily. The dose of glibenclamide was subsequently reduced and 10 months after transition the patient required only 0.62 mg/kg body weight glibenclamide daily. No hypoglycemia has been reported in the patient since she started on glibenclamide.
Seven months after starting glibenclamide treatment a pediatric neurological examination was normal. The child no longer had running problems (she fell down infrequently less than twice a week) and showed considerable improvement in sustaining attention. She was able to draw simple pictures, write a few letters and digits and clean her teeth by herself, none of which was observed before drug therapy. She now fulfilled only three criteria for inattention and five for hyperactivity-impulsivity (DSM-IV diagnostic criteria for ADHD). Mental development assessment using the WPPSI-R test still showed mild mental retardation but her intelligence had improved (IQ 71).
A second SPECT examination performed 16 weeks after insulin was discontinued revealed that the focal perfusion deficit in the left temporal cortex observed in the initial examination was no longer present ( Figure 1B 
DISCUSSION OF DIAGNOSIS
DEND syndrome is defined as developmental delay with epilepsy, muscle weakness and neonatal diabetes and is caused by mutations in the K ATP channel subunits Kir6.2 (encoded by KCNJ11) or SUR1 (sulfonylurea receptor 1; encoded by ABCC8). 2 Intermediate DEND syndrome (iDEND) is a less severe condition in which neonatal diabetes is accompanied by muscle weakness and developmental delay but not epilepsy. 2 To date, two KCNJ11 mutations have been shown to cause iDEND in some but not all patients: 4 of 5 patients with Val59Met and 2 of 7 patients with Arg201Cys had iDEND. 2, 5, 6 These patients were characterized by low birth weight (mean ~2.5 kg; percentile for weight 0.8-2.4%) despite normal gestational age, neonatal diabetes (mean age at diagnosis 5-6 weeks), muscle weakness, and motor and Table 2 online) . 2, 6 The symptoms of the patient discussed in this Case Study were consistent with iDEND, and a mutation in KCNJ11 was confirmed by sequencing this gene. Mutations in KCNJ11 that cause iDEND act by reducing the ability of cellular ATP to block to the K ATP channel. 1,2,7 As a consequence, the channel remains open when blood glucose levels rise, preventing insulin secretion. 2 As the mutation (His46Leu) carried by this patient was novel, in vitro functional analysis was used to confirm that the mutation reduced K ATP channel ATP sensitivity ( Figure 2C ,D and Supplementary Information 1 online) .
Approximately 50% of patients with low birth weight who present with permanent neonatal diabetes within the first 6 months of life have mutations in KCNJ11 or ABCC8. 2, 6 Antiislet autoantibodies are usually absent. These characteristics differentiate neonatal diabetes from type 1 diabetes, which presents later and in which autoantibodies are present. Neurological features are associated with some KCNJ11 and ABCC8 mutations, 2, 5, 6 but the extent of impairment of neurological function can vary, so patients should be assessed by a neurologist for muscle weakness and motor and mental developmental delay as well as epilepsy. These children might walk and talk later than normal.
TREATMENT AND MANAGEMENT
Recent evidence has shown that patients with gain-of-function mutations in KCNJ11 can be successfully treated with sulfonylureas, which block open K ATP channels. 8 This treatment removes the necessity for daily insulin injections and markedly enhances glycemic control. [3] [4] [5] Functional studies revealed that K ATP channels heterozygous for the His46Leu mutation (as would be the case in the current patient) exhibit a marked sensitivity to inhibition by the sulfonylurea tolbutamide ( Figure 2E ). When tolbutamide causes a block of this magnitude, patients carrying the relevant KCNJ11 mutations generally respond well to sulfonylurea therapy. 3 Consequently, sulfonylurea therapy was initiated in the patient presented here, resulting in improved glycemic control and a reduction in Hb A1c levels.
Remediation of this patient's neurological symptoms and mental status suggests that glibenclamide blocks K ATP channels in neurons enough to normalize electrical activity and transmitter release, as it presumably does in β-cells. The improvements in brain blood flow and in motor and mental function are consistent with the high density of K ATP channels found in the cerebellum and cerebral cortex. 9, 10 The increase in blood flow observed in the SPECT scans is most likely to reflect an increase in neuronal activity, rather than a direct effect on vascular tissue, because β-cell and neuronal (Kir6.2-SUR1) K ATP channels are more sensitive to glibenclamide block than are vascular (Kir6.2-SUR2B) K ATP channels. 11 As relatively good glycemic control was achieved before both SPECT examinations, it is unlikely that variability in glucose levels had a large impact on the SPECT images. This finding is consistent with a previous SPECT study of pediatric patients with type 1 diabetes, which found that perfusion of the cerebellum and temporal lobe differed little between those patients with well-controlled and those with poorly controlled diabetes, or between patients with diabetes and healthy subjects. 12 Although we cannot exclude the possibility that the current patient's increased IQ score was attributable, at least in part, to the natural course of the disease, the magnitude of the response and the short time interval (10 months) between the two sets of WPPSI-R tests make this an unlikely scenario. It is possible that the observed increase in IQ was partly a result of the improvement in ADHD symptoms produced by glibenclamide.
A major difference between insulin therapy and sulfonylurea treatment is that the former only controls glucose homeostasis whereas sulfonylureas should block K ATP channels in all tissues to which they have access, and, therefore, alleviate extrapancreatic problems. Although the extent to which sulfonylureas cross the bloodbrain barrier is unknown in humans, limited penetrance has been documented in rodents. 13 The improvements in mental and motor function, and in brain blood flow, observed in the patient in this case following glibenclamide treatment suggest that the drug is able to access the brain at concentrations sufficient to influence K ATP channel activity.
CONCLUSIONS
This Case Study describes a novel KCNJ11 mutation, His46Leu, causing iDEND syndrome. Sulfonylurea (glibenclamide) therapy not only restored glucose homeostasis, but also alleviated some of the neurological symptoms associated with the patient's impaired CNS function. Good long-term glycemic control together with an improvement in motor function following glibenclamide treatment has recently been reported in a patient with iDEND, 5 but the impact of this treatment on the CNS has not yet been documented. Here we show for the first time that CNS blood flow and function can be improved by sulfonylureas. This study is the first to report the use of SPECT to provide evidence of brain changes that correlate with mental and motor improvement following glibenclamide therapy. This finding does not, of course, prove a causal relationship between the changes in brain perfusion and psychomotor function.
This Case Study re-emphasizes the necessity of screening for K ATP channel mutations in diabetes diagnosed before the age of 6 months, especially if developmental delay is also present. Furthermore, introduction of sulfonylurea treatment in patients carrying K ATP channel mutations should be implemented as soon as possible, not only to improve glycemic control, but also to help alleviate neurological problems.
Supplementary Information in the form of text, tables and figures is available on the Nature Clinical Practice Neurology website.
